[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629762":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":48,"collaborators":50,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":20,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":20,"enrollmentInfo":65,"targetDuration":20,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":78,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Johns Hopkins University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Corrie Lipids Program","EXPERIMENTAL","Multicomponent digital health lipid management and education program",[13],"Device: Corrie Lipids Digital Health Program",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Corrie Lipids Digital Health Program","The Corrie Lipids Program is a digital health initiative for adults with uncontrolled LDL-C and high ASCVD risk. It includes a smartphone app for LDL-C tracking, medication reminders, and education, along with clinician education and support to improve guideline-directed lipid management.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Stacey Schott, MD, MPH","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Francoise Marvel, MD","CONTACT","410-502-0469","fmarvel1@jhmi.edu",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Johns Hopkins University School of Medicine","RECRUITING","Baltimore","Maryland","21287","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-76.61219,39.29038,{"lat":44,"lon":43},[47],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"type":49,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[51,54],{"name":52,"class":53},"Amgen","INDUSTRY",{"name":55,"class":53},"NewAmsterdam Pharma","100629762","impact-of-the-corrie-lipids-digital-health-program-on-lipid-optimization-100629762",false,"NCT07478887","Impact of the Corrie Lipids Digital Health Program on Lipid Optimization","Corrie Lipids Program: Optimizing LDL-Cholesterol by Improving Awareness, Access, and Achievement","Inclusion Criteria:\n\n* Age ≥18 years\n* Uncontrolled LDL-C per AHA\u002FACC guidelines\n* At least 1 major cardiovascular risk factor, including: high risk for ASCVD (individuals who meet criteria for Lipid-Lowering Therapy (LLT) based on ASCVD risk assessment using the most up-to-date guidelines), known ASCVD or subclinical ASCVD based on imaging, clinically diagnosed familial hypercholesterolemia or LDL-C ≥190 mg\u002FdL, diabetes mellitus, history of statin-associated side effects\n* Has a primary care physician and\u002For cardiologist who can prescribe lipid therapy\n* Owns a smartphone and agrees to the End User License Agreement to use the digital health app\n* Provided informed consent before initiation of study-specific activities\n\nExclusion Criteria:\n\n* Motor, cognitive, auditory, or visual impairment limiting technology use\n* Does not speak English\n* Malignancy (except nonmelanoma skin cancers or cervical or breast ductal carcinoma in situ within the previous 5 years)\n* Pregnancy (positive pregnancy test, highly sensitive urine or serum), plan to become pregnant or donate eggs, breastfeeding or plan to breastfeed\n* Likely to not be available to comply with all required study procedures to the best of the patient's and investigator's knowledge\n* History or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator, would pose a risk to patient safety or interfere with the study evaluation, procedures, or completion","ALL","18 Years",{"count":66,"type":67},1000,"ESTIMATED","INTERVENTIONAL",[70],"NA","The overall objective is to evaluate the effectiveness and implementation of the Corrie Lipids Program, a comprehensive digital health initiative designed to address critical gaps in lipid-lowering as a component of ASCVD treatment by delivering an intervention that combines a patient-facing smartphone app, clinician education and coaching, and seamless incorporation into clinical workflows.\n\nResearchers plan to assess this multicenter digital health initiative in approximately 1,000 adults with uncontrolled LDL-C and elevated ASCVD risk using the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework. The study will examine whether the program improves LDL-C goal attainment, app engagement, prescribing patterns, and LDL-C monitoring, while also identifying barriers and facilitators to implementation across sites.",[73,74,75,76,77],"Cardiovascular Risk","LDL-C","Lipids","Digital Health","Implementation Science",[79,80],"Apolipoprotein B (apoB)","Lipoprotein-a (Lp(a)","2026-03-13",{"date":83,"type":84},"2026-03-18","ACTUAL",{"date":86,"type":84},"2025-06-20",{"date":88,"type":67},"2027-12",{"name":5,"class":6},1]